Table 2.

Tocilizumab administration, diagnostic time, treatment of invasive aspergillosis, and outcomes.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
First tocilizumab dose	5.2 mg/kg	11 mg/kg	4 mg/kg	7.5 mg/kg	6.25 mg/kg	6 mg/kg
Second tocilizumab dose	5.2 mg/kg	n/a	4 mg/kg	7.5 mg/kg	3.1 mg/kg	6 mg/kg
Days between 1ST and 2nd tocilizumab dose	3	n/a	4	6	8	11
Total cumulative tocilizumab dose	10.4 mg/kg	11 mg/kg	8 mg/kg	15 mg/kg	9.38 mg/kg	12.12 mg/kg
Status of capa $	Probable	Probable	Probable	Probable	Probable	Probable
Usage of penicillin before diagnosis	No	No	Yes, piperacillin/tazobactam	Yes, piperacillin/tazobactam	No	No
Blood Aspergillus AG titer while IA diagnosed	0.69	0.61	0.73	1.82	0.76	1.09
The highest blood ASPERGILLUS AG titer	1.60	6.62	1.14	3.17	2.26	4.71
The highest BAL ASPERGILLUS AG titer	7.09	0.89	0.36	0.76	0.26	0.41
Imagine evidence of aspergillosis in chest CT	N/A	Nonspecific findings	N/A	Clusters of fluffy nodules	Diffuse ground glass opacity with reticulations	Diffuse ground glass opacity with consolidations
Days after COVID-19 symptom onset to IA diagnosed	32	32	15	21	20	27
Days after ICU admission to IA diagnosed	28	19	6	18	11	10
Days after 1ST tocilizumab dose to IA diagnosed	28	26	9	13	11	21
Days after 2nd tocilizumab dose to IA diagnosed	25	n/a	5	7	3	10
Antifungal agent	Voriconazole	Voriconazole + caspofungin, switched to posaconazole	Voriconazole	Voriconazole, add-on caspofungin	Voriconazole + micafungin, switched to posaconazole	Voriconazole, add-on caspofungin
Outcomes	Death on Day 51	Death on Day 168	Discharged on Day 28	Discharged on Day 76	Discharged on Day 61	Discharged on Day 151 (respiratory care ward)

Note: n/a: not applicable; IA: invasive aspergillosis; Ag: antigen; ICU: Intensive Care Unit; CAPA: COVID-19-associated pulmonary aspergillosis; BAL: bronchoalveolar lavage; CT: computed tomography. ^$: according to Koehler 2020, Lancet Infect Dis [7].